Gsk (GLAXF) Current Deferred Revenue (2016 - 2018)

Gsk's Current Deferred Revenue history runs 3 years deep, the most recent figure standing at $277.9 million for Q4 2018.

• In Q4 2018, Current Deferred Revenue fell 12.77% year-over-year to $277.9 million; the TTM figure through Dec 2018 stood at $277.9 million (down 12.77% YoY), while the FY2018 annual figure was $288.5 million, down 6.69% from the prior year.
• Current Deferred Revenue was $277.9 million for Q4 2018 at Gsk, down from $318.6 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $318.6 million in Q4 2017 to a low of $196.4 million in Q4 2016.
• Historically, Current Deferred Revenue has averaged $264.3 million across 3 years, with a median of $277.9 million in 2018.
• The sharpest annual moves came in 2017 and 2018: Current Deferred Revenue jumped 62.22% in 2017, then decreased 12.77% in 2018.
• A 3-year view of Current Deferred Revenue shows it stood at $196.4 million in 2016, then jumped by 62.22% to $318.6 million in 2017, then retreated by 12.77% to $277.9 million in 2018.
• The last three Current Deferred Revenue figures came in at $277.9 million (Q4 2018), $318.6 million (Q4 2017), and $196.4 million (Q4 2016), per Business Quant data.